Astraveus SAS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Astraveus SAS - overview
Established
2016
Location
Paris, -, France
Primary Industry
Biotechnology
About
Based in Paris, France, and founded in 2016 by CEO Jeremie Lauren, Astraveus SAS operates as a biotechnology company that develops a microfluidic cell foundry that facilitates the creation and production of the majority of cell and gene therapies. In June 2023, Astraveus SAS raised EUR 16. 5 million in seed funding led by AdBio Partners, with participation from other CDC Enterprises, Johnson & Johnson Innovation, and M Ventures. In October 2023, Astraveus SAS received EUR 10.
4 million in grant funding frominvestor Government of France. Astraveus offers a CGT (cell and gene therapy) manufacturing platform, Lakhesys, used to optimize and miniaturize cellular therapies. The company’s platform uses microfluidic bioprocessors to miniaturize and automate cell and gene therapy manufacturing, which includes CAR-T cells and hematopoietic stem cells (HSCs) that produce blood cells. The company plans to use the October 2023 funding to further develop its Lakhesys platform.
Current Investors
Johnson & Johnson Innovation, Bpifrance, AdBio Partners
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.astraveus.com
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.